Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2013

View Archived Issues

ADAM10: potential target and genetic marker for late-onset AD

Discovery of a broad-genotype inhibitor of HCV replication

AllaChem completes phase I study of AV-4025

Hasselt University and Inova Diagnostics collaborate on biomarkers for RA

AstraZeneca selects miRNA oncology target under alliance with Regulus Therapeutics

STADA in-licenses approved biosimilar from Apotex

Santaris resumes full ownership of LNA programs licensed to Enzon

BELLUS Health and AmorChem sign co-development agreement for AL amyloidosis

BioTime discloses interim results from safety study of Renevia

Phase I/II trial of vosaroxin in myelodysplastic syndrome begins

Sophiris begins dosing in PLUS-1 phase III trial of PRX-302

Etanercept biosimilar product meets primary endpoint in pivotal study

Updated clinical data on nintedanib reported

Crown Bioscience describes patient-derived xenografts for testing CBI-3103

Bristol-Myers Squibb reports developments of third quarter 2013

University of South Florida discloses new myricanol derivatives

French team presents novel diagnostics for Alzheimer's disease

Novartis reports progress during third quarter 2013

Polish researchers patent new bacterial efflux pump inhibitors

Researchers at Apac Pharmaceutical synthesize novel agents for arthritis

Pharmacodynamic activity seen for AMG-811 in patients with SLE

Janssen Pharmaceutica divulges new CCR2 receptor antagonists

Stemline Therapeutics to accelerate development of SL-401 in hematologic cancers

Cara Therapeutics reports results from phase II trial of CR-845

Novel osteoporosis mouse models carry human RANKL gene

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...